| CARSON CITY, Nev., Feb. 21, 2012 /PRNewswire/ -- OphthaliX (OTCBB: OPLI) announced that the Chinese State Intellectual Property Office (SIPO) issued a Certificate of Patent Invention for Chinese Patent Application No. 200680047569.7 entitled "Adenosine A3 receptor agonists for the treatment of dry eye disorders". This patent is related to OphthaliX drug candidate CF101 and will grant OphthaliX exclusive rights for the use of CF101 for the treatment of dry eye syndrome in the People's Republic of Chi...continued OPLI |
Tuesday, February 21, 2012
OphthaliX Announces Issuance of Chinese Patent for the Treatment of Dry Eye Disorders
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment